Skip to main content
Top
Published in: Journal of Endocrinological Investigation 8/2016

01-08-2016 | Review

Endocrine dysfunction in hereditary hemochromatosis

Authors: C. Pelusi, D. I. Gasparini, N. Bianchi, R. Pasquali

Published in: Journal of Endocrinological Investigation | Issue 8/2016

Login to get access

Abstract

Hereditary hemochromatosis (HH) is a genetic disorder of iron overload and subsequent organ damage. Five types of HH are known, classified by age of onset, genetic cause, clinical manifestations and mode of inheritance. Except for the rare form of juvenile haemochromatosis, symptoms do not usually appear until after decades of progressive iron loading and may be triggered by environmental and lifestyle factors. Despite the last decades discovery of genetic and phenotype diversity of HH, early studies showed a frequent involvement of the endocrine glands where diabetes and hypogonadism are the most common encountered endocrinopathies. The pathogenesis of diabetes is still relatively unclear, but the main mechanisms include the loss of insulin secretory capacity and insulin resistance secondary to liver damage. The presence of obesity and/or genetic predisposition may represent addictive risk factor for the development of this metabolic disease. Although old cases of primary gonad involvement are described, hypogonadism is mainly secondary to selective deposition of iron on the gonadotropin-producing cells of the pituitary gland, leading to hormonal impaired secretion. Cases of hypopituitarism or selected tropin defects, and abnormalities of adrenal, thyroid and parathyroid glands, even if rare, are reported. The prevalence of individual gland dysfunction varies enormously within studies for several bias due to small numbers of and selected cases analyzed, mixed genotypes and missing data on medical history. Moreover, in the last few years early screening and awareness of the disease among physicians have allowed hemochromatosis to be diagnosed in most cases at early stages when patients have no symptoms. Therefore, the clinical presentation of this disease has changed significantly and the recognized common complications are encountered less frequently. This review summarizes the current knowledge on HH-associated endocrinopathies.
Literature
2.
go back to reference Pietrangelo A (2010) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139:393–408CrossRefPubMed Pietrangelo A (2010) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139:393–408CrossRefPubMed
4.
go back to reference Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, Consonni D, Coviello E, Conte D, Fargion S (2010) Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 51:501–510CrossRefPubMed Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, Consonni D, Coviello E, Conte D, Fargion S (2010) Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 51:501–510CrossRefPubMed
5.
go back to reference Wood M, Powell LW, Ramm GA (2008) Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111:4456–4462CrossRefPubMed Wood M, Powell LW, Ramm GA (2008) Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111:4456–4462CrossRefPubMed
6.
go back to reference Majore S, Milano F, Binni F, Stuppia L, Cerrone A, Tafuri A, DeBernardo C, Palka G, Grammatico P (2006) Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. Haematologica 91(8 Suppl):ECR33 Majore S, Milano F, Binni F, Stuppia L, Cerrone A, Tafuri A, DeBernardo C, Palka G, Grammatico P (2006) Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. Haematologica 91(8 Suppl):ECR33
7.
go back to reference De Gobbi M, Roetto A, Piperno A et al (2002) Natural history of juvenile haemochromatosis. Br J Haematol 117:973–979CrossRefPubMed De Gobbi M, Roetto A, Piperno A et al (2002) Natural history of juvenile haemochromatosis. Br J Haematol 117:973–979CrossRefPubMed
8.
go back to reference Capell P (2004) Haemochromatosis in type 2 diabetes. Clin Diabetes 22:101–102CrossRef Capell P (2004) Haemochromatosis in type 2 diabetes. Clin Diabetes 22:101–102CrossRef
9.
go back to reference Wieringa D, Rankin M (2010) Hemochromatosis and diabetes mellitus: the ‘bronze diabetes’. Aust Diabetes Educ 13:4 Wieringa D, Rankin M (2010) Hemochromatosis and diabetes mellitus: the ‘bronze diabetes’. Aust Diabetes Educ 13:4
10.
go back to reference Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ (2010) Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism 59:380–384CrossRefPubMed Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ (2010) Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism 59:380–384CrossRefPubMed
11.
go back to reference O’Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH (2008) Declining prevalence of diabetes mellitus in hereditary haemochromatosis-the result of earlier diagnosis. Diabetes Res Clin Pract 81:316–320CrossRefPubMed O’Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH (2008) Declining prevalence of diabetes mellitus in hereditary haemochromatosis-the result of earlier diagnosis. Diabetes Res Clin Pract 81:316–320CrossRefPubMed
12.
go back to reference Njajou OT, de Jong G, Berghuis B et al (2002) Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. Blood Cells Mol Dis. 29:439–443CrossRefPubMed Njajou OT, de Jong G, Berghuis B et al (2002) Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. Blood Cells Mol Dis. 29:439–443CrossRefPubMed
13.
go back to reference Creighton Mitchell T, McClain DA (2014) Diabetes and hemochromatosis. Curr Diabetes Rep 14:488CrossRef Creighton Mitchell T, McClain DA (2014) Diabetes and hemochromatosis. Curr Diabetes Rep 14:488CrossRef
14.
go back to reference Utzschneider KM, Kowdley K (2010) Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. Nat Rev Endocrinol 6:26–33CrossRefPubMed Utzschneider KM, Kowdley K (2010) Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. Nat Rev Endocrinol 6:26–33CrossRefPubMed
15.
go back to reference McClain DA, Abraham D, Rogers J et al (2006) High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 49:1661–1669CrossRefPubMed McClain DA, Abraham D, Rogers J et al (2006) High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 49:1661–1669CrossRefPubMed
16.
go back to reference Zhou XY, Tomatsu S, Fleming RE et al (1998) HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 95:2492–2497CrossRefPubMedPubMedCentral Zhou XY, Tomatsu S, Fleming RE et al (1998) HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 95:2492–2497CrossRefPubMedPubMedCentral
17.
go back to reference Cooksey RC, Jouihan HA, Ajioka RS et al (2004) Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145:5305–5312CrossRefPubMed Cooksey RC, Jouihan HA, Ajioka RS et al (2004) Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145:5305–5312CrossRefPubMed
18.
go back to reference Hramiak IM, Finegood DT, Adams PC (1997) Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 20:110–118PubMed Hramiak IM, Finegood DT, Adams PC (1997) Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 20:110–118PubMed
20.
go back to reference Barton JC, Barton JC, Acton RT (2014) Diabetes in first-degree family members: a predictor of type 2 diabetes in 159 nonscreening Alabama hemochromatosis probands with HFE C282Y homozygosity. Diabetes Care 37:259–266CrossRefPubMed Barton JC, Barton JC, Acton RT (2014) Diabetes in first-degree family members: a predictor of type 2 diabetes in 159 nonscreening Alabama hemochromatosis probands with HFE C282Y homozygosity. Diabetes Care 37:259–266CrossRefPubMed
21.
go back to reference Ellervik C, Mandrup-Poulsen T, Nordestgaard BG et al (2001) Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 358:1405–1409CrossRefPubMed Ellervik C, Mandrup-Poulsen T, Nordestgaard BG et al (2001) Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 358:1405–1409CrossRefPubMed
22.
go back to reference Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ (2010) Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism 59:1811–1815CrossRefPubMed Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ (2010) Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism 59:1811–1815CrossRefPubMed
23.
go back to reference Bomford A, Williams R (1976) Long term results of venesection in idiopathic haemochromatosis. Q J Med 45:611–623PubMed Bomford A, Williams R (1976) Long term results of venesection in idiopathic haemochromatosis. Q J Med 45:611–623PubMed
24.
go back to reference Bergeron C, Kovacs K (1978) Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am J Pathol 93:295–309PubMedPubMedCentral Bergeron C, Kovacs K (1978) Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am J Pathol 93:295–309PubMedPubMedCentral
25.
go back to reference McNeil LW, McKee LC Jr, Lorber D, Rabin D (1983) The endocrine manifestations of hemochromatosis. Am J Med Sci 285:7–13CrossRefPubMed McNeil LW, McKee LC Jr, Lorber D, Rabin D (1983) The endocrine manifestations of hemochromatosis. Am J Med Sci 285:7–13CrossRefPubMed
26.
go back to reference Walsh CH, Wright AD, Williams JW, Holder G (1976) A study of pituitary function in patients with idiopathic hemochromatosis. J Clin Endocrinol Metab 43:866–872CrossRefPubMed Walsh CH, Wright AD, Williams JW, Holder G (1976) A study of pituitary function in patients with idiopathic hemochromatosis. J Clin Endocrinol Metab 43:866–872CrossRefPubMed
27.
28.
go back to reference Tournaire J, Fevre M, Mazenod B, Ponsin G (1974) Effects of clomiphene citrate and synthetic LHRH on serum luteinizing hormone (LH) in men with idiopathic hemochromatosis. J Clin Endocrinol Metab 38:1122–1124CrossRefPubMed Tournaire J, Fevre M, Mazenod B, Ponsin G (1974) Effects of clomiphene citrate and synthetic LHRH on serum luteinizing hormone (LH) in men with idiopathic hemochromatosis. J Clin Endocrinol Metab 38:1122–1124CrossRefPubMed
29.
go back to reference Charbonnel B, Chupin M, Le GA, Guillon J (1981) Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) 98:178–183 Charbonnel B, Chupin M, Le GA, Guillon J (1981) Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) 98:178–183
30.
go back to reference Kley HK, Stremmel W, Niederau C et al (1985) Androgen and estrogen response to adrenal and gonadal stimulation in idiopathic hemochromatosis: evidence for decreased estrogen formation. Hepatology 5:251–256CrossRefPubMed Kley HK, Stremmel W, Niederau C et al (1985) Androgen and estrogen response to adrenal and gonadal stimulation in idiopathic hemochromatosis: evidence for decreased estrogen formation. Hepatology 5:251–256CrossRefPubMed
31.
go back to reference Piperno A, Rivolta MR, D’Alba R et al (1992) Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction. J Endocrinol Invest 15:423–428CrossRefPubMed Piperno A, Rivolta MR, D’Alba R et al (1992) Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction. J Endocrinol Invest 15:423–428CrossRefPubMed
32.
go back to reference Duranteau L, Chanson P, Blumberg-Tick J et al (1993) Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. Acta Endocrinol (Copenh) 128:351–354 Duranteau L, Chanson P, Blumberg-Tick J et al (1993) Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. Acta Endocrinol (Copenh) 128:351–354
33.
go back to reference McDermott JH, Walsh CH (2005) Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 90:2451–2455CrossRefPubMed McDermott JH, Walsh CH (2005) Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 90:2451–2455CrossRefPubMed
34.
go back to reference Kelly TM, Edwards CQ, Meikle AW, Kushner JP (1984) Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 101:629–632CrossRefPubMed Kelly TM, Edwards CQ, Meikle AW, Kushner JP (1984) Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 101:629–632CrossRefPubMed
35.
go back to reference Bhansali A, Banerjee PK, Dash S, Radotra B, Dash RJ (1992) Pituitary and testicular involvement in primary haemochromatosis. A case report. J Assoc Physicians India 40:757–759PubMed Bhansali A, Banerjee PK, Dash S, Radotra B, Dash RJ (1992) Pituitary and testicular involvement in primary haemochromatosis. A case report. J Assoc Physicians India 40:757–759PubMed
36.
go back to reference Siminoski K, D’Costa M, Walfish PG (1990) Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. J Endocrinol Invest 13:849–853CrossRefPubMed Siminoski K, D’Costa M, Walfish PG (1990) Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. J Endocrinol Invest 13:849–853CrossRefPubMed
37.
go back to reference Stremmel W, Kley HK, Kruskemper HL, Strohmeyer G (1985) Differing abnormalities in estrogen and androgen and insulin metabolism in idiopathic hemochromatosis versus alcoholic liver disease. Semin Liver Dis 5:84–93CrossRefPubMed Stremmel W, Kley HK, Kruskemper HL, Strohmeyer G (1985) Differing abnormalities in estrogen and androgen and insulin metabolism in idiopathic hemochromatosis versus alcoholic liver disease. Semin Liver Dis 5:84–93CrossRefPubMed
38.
go back to reference Lamon JM, Marynick SP, Roseblatt R, Donnelly S (1979) Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology 76:178–183PubMed Lamon JM, Marynick SP, Roseblatt R, Donnelly S (1979) Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology 76:178–183PubMed
39.
go back to reference Tweed MJ, Roland JM (1998) Haemochromatosis as an endocrine cause of subfertility. Br Med J 316:915–916CrossRef Tweed MJ, Roland JM (1998) Haemochromatosis as an endocrine cause of subfertility. Br Med J 316:915–916CrossRef
40.
go back to reference Farina G, Pedrotti C, Cerani P et al (1995) Successful pregnancy following gonadotropin therapy in a young female with juvenile idiopathic hemochromatosis and secondary hypogonadotropic hypogonadism. Haematologica 80:335–337PubMed Farina G, Pedrotti C, Cerani P et al (1995) Successful pregnancy following gonadotropin therapy in a young female with juvenile idiopathic hemochromatosis and secondary hypogonadotropic hypogonadism. Haematologica 80:335–337PubMed
41.
go back to reference Militaru MS, Popp RA, Trifa AP (2010) Homozygous G320 V mutation in the HJV gene causing juvenile hereditary haemochromatosis type A. A case report. J Gastrointestin Liver Dis 19:191–193PubMed Militaru MS, Popp RA, Trifa AP (2010) Homozygous G320 V mutation in the HJV gene causing juvenile hereditary haemochromatosis type A. A case report. J Gastrointestin Liver Dis 19:191–193PubMed
42.
go back to reference Cundy T, Butler J, Bomford A, Williams R (1993) Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 38:617–620CrossRef Cundy T, Butler J, Bomford A, Williams R (1993) Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 38:617–620CrossRef
43.
44.
go back to reference Hamer OW, Gnad M, Scholmerich J, Palitzsch KD (2001) Successful treatment of erectile dysfunction and infertility by venesection in a patient with primary haemochromatosis. Eur J Gastroenterol Hepatol 13:985–988CrossRefPubMed Hamer OW, Gnad M, Scholmerich J, Palitzsch KD (2001) Successful treatment of erectile dysfunction and infertility by venesection in a patient with primary haemochromatosis. Eur J Gastroenterol Hepatol 13:985–988CrossRefPubMed
45.
go back to reference Hudec M, Grigerova M, Walsh CH (2008) Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion. Thyroid 18:255–257CrossRefPubMed Hudec M, Grigerova M, Walsh CH (2008) Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion. Thyroid 18:255–257CrossRefPubMed
46.
go back to reference Lufkin EG, Baldus WP, Bergstralh EJ, Kao PC (1987) Influence of phlebotomy treatment on abnormal hypothalamic-pituitary function in genetic hemochromatosis. Mayo Clin Proc 62:473–479CrossRefPubMed Lufkin EG, Baldus WP, Bergstralh EJ, Kao PC (1987) Influence of phlebotomy treatment on abnormal hypothalamic-pituitary function in genetic hemochromatosis. Mayo Clin Proc 62:473–479CrossRefPubMed
47.
go back to reference Hempenius LM, Van Dam PS, Marx JJ, Koppeschaar HP (1999) Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis. J Endocrinol Invest 22:369–376CrossRefPubMed Hempenius LM, Van Dam PS, Marx JJ, Koppeschaar HP (1999) Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis. J Endocrinol Invest 22:369–376CrossRefPubMed
48.
go back to reference MacDonald RA, Mallory GK (1960) Hemochromatosis and hemosiderosis. Study of 211 autopsied cases. Arch Intern Med 105:686–700CrossRefPubMed MacDonald RA, Mallory GK (1960) Hemochromatosis and hemosiderosis. Study of 211 autopsied cases. Arch Intern Med 105:686–700CrossRefPubMed
49.
go back to reference Edwards CQ, Kelly TM, Ellwein G, Kushner JP (1983) Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 143:1890–1893CrossRefPubMed Edwards CQ, Kelly TM, Ellwein G, Kushner JP (1983) Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 143:1890–1893CrossRefPubMed
51.
go back to reference Tamagno G, De CE, Murialdo G, Scandellari C (2007) A possible link between genetic hemochromatosis and autoimmune thyroiditis. Minerva Med 98:769–772PubMed Tamagno G, De CE, Murialdo G, Scandellari C (2007) A possible link between genetic hemochromatosis and autoimmune thyroiditis. Minerva Med 98:769–772PubMed
52.
go back to reference Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH (2008) Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study. Thyroid 18:831–838CrossRefPubMedPubMedCentral Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH (2008) Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study. Thyroid 18:831–838CrossRefPubMedPubMedCentral
53.
54.
go back to reference Barton JC, Rao SV, Pereira NM et al (2002) Juvenile hemochromatosis in the southeastern United States: a report of seven cases in two kinships. Blood Cells Mol Dis 29:104–115CrossRefPubMed Barton JC, Rao SV, Pereira NM et al (2002) Juvenile hemochromatosis in the southeastern United States: a report of seven cases in two kinships. Blood Cells Mol Dis 29:104–115CrossRefPubMed
55.
go back to reference Walsh CH, Murphy AL, Cunningham S, McKenna TJ (1994) Mineralocorticoid and glucocorticoid status in idiopathic haemochromatosis. Clin Endocrinol (Oxf) 41:439–443CrossRef Walsh CH, Murphy AL, Cunningham S, McKenna TJ (1994) Mineralocorticoid and glucocorticoid status in idiopathic haemochromatosis. Clin Endocrinol (Oxf) 41:439–443CrossRef
56.
go back to reference Varkonyi J, Kaltwasser JP, Seidl C, Kollai G, Andrikovics H, Tordai A (2000) A case of non-HFE juvenile haemochromatosis presenting with adrenocortical insufficiency. Br J Haematol 109:252–253CrossRefPubMed Varkonyi J, Kaltwasser JP, Seidl C, Kollai G, Andrikovics H, Tordai A (2000) A case of non-HFE juvenile haemochromatosis presenting with adrenocortical insufficiency. Br J Haematol 109:252–253CrossRefPubMed
57.
go back to reference Thomas JP (1984) Aldosterone deficiency in a patient with idiopathic haemochromatosis. Clin Endocrinol (Oxf) 21:271–277CrossRef Thomas JP (1984) Aldosterone deficiency in a patient with idiopathic haemochromatosis. Clin Endocrinol (Oxf) 21:271–277CrossRef
58.
go back to reference Conway SP, Dudley N, Sheridan P, Ross H (1989) Haemochromatosis and aldosterone deficiency presenting with Yersinia pseudotuberculosis septicaemia. Postgrad Med J 65:174–176CrossRefPubMedPubMedCentral Conway SP, Dudley N, Sheridan P, Ross H (1989) Haemochromatosis and aldosterone deficiency presenting with Yersinia pseudotuberculosis septicaemia. Postgrad Med J 65:174–176CrossRefPubMedPubMedCentral
59.
go back to reference Pawlotsky Y, Roussey M, Hany Y, Simon M, Bourel M (1974) Increased blood parathormone levels in idiopathic hemochromatosis. Nouv Presse Med 3:1757–1758PubMed Pawlotsky Y, Roussey M, Hany Y, Simon M, Bourel M (1974) Increased blood parathormone levels in idiopathic hemochromatosis. Nouv Presse Med 3:1757–1758PubMed
60.
go back to reference Diamond T, Stiel D, Posen S (1989) Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 110:430–436CrossRefPubMed Diamond T, Stiel D, Posen S (1989) Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 110:430–436CrossRefPubMed
61.
go back to reference Guggenbuhl P, Deugnier Y, Boisdet JF et al (2005) Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16:1809–1814CrossRefPubMed Guggenbuhl P, Deugnier Y, Boisdet JF et al (2005) Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16:1809–1814CrossRefPubMed
62.
go back to reference Pawlotsky Y, Le DP, Moirand R et al (1999) Elevated parathyroid hormone 44–68 and osteoarticular changes in patients with genetic hemochromatosis. Arthritis Rheum 42:799–806CrossRefPubMed Pawlotsky Y, Le DP, Moirand R et al (1999) Elevated parathyroid hormone 44–68 and osteoarticular changes in patients with genetic hemochromatosis. Arthritis Rheum 42:799–806CrossRefPubMed
63.
go back to reference Conte D, Caraceni MP, Duriez J et al (1989) Bone involvement in primary hemochromatosis and alcoholic cirrhosis. Am J Gastroenterol 84:1231–1234PubMed Conte D, Caraceni MP, Duriez J et al (1989) Bone involvement in primary hemochromatosis and alcoholic cirrhosis. Am J Gastroenterol 84:1231–1234PubMed
64.
go back to reference Valenti L, Varenna M, Fracanzani AL et al (2009) Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20:549–555CrossRefPubMed Valenti L, Varenna M, Fracanzani AL et al (2009) Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20:549–555CrossRefPubMed
65.
go back to reference Yamasaki K, Hagiwara H (2009) Excess iron inhibits osteoblast metabolism. Toxicol Lett 191:211–215CrossRefPubMed Yamasaki K, Hagiwara H (2009) Excess iron inhibits osteoblast metabolism. Toxicol Lett 191:211–215CrossRefPubMed
66.
go back to reference Guggenbuhl P, Filmon R, Mabilleau G, Basle MF, Chappard D (2008) Iron inhibits hydroxyapatite crystal growth in vitro. Metabolism 57:903–910CrossRefPubMed Guggenbuhl P, Filmon R, Mabilleau G, Basle MF, Chappard D (2008) Iron inhibits hydroxyapatite crystal growth in vitro. Metabolism 57:903–910CrossRefPubMed
67.
go back to reference Angelopoulos NG, Goula AK, Papanikolaou G, Tolis G (2006) Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporos Int 17:150–155CrossRefPubMed Angelopoulos NG, Goula AK, Papanikolaou G, Tolis G (2006) Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporos Int 17:150–155CrossRefPubMed
68.
go back to reference Diamond T, Stiel D, Posen S (1991) Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 6:39–43CrossRefPubMed Diamond T, Stiel D, Posen S (1991) Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 6:39–43CrossRefPubMed
69.
go back to reference Eyres KS, McCloskey EV, Fern ED et al (1992) Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone 13:431–433CrossRefPubMed Eyres KS, McCloskey EV, Fern ED et al (1992) Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone 13:431–433CrossRefPubMed
70.
go back to reference Hibbert EJ, Fulcher GR, Coyle L, Gates F, Clifton-Bligh P, Stiel D (1999) Effect of venesection on bone mineral density in an eugonadal woman with haemochromatosis. J Gastroenterol Hepatol 14:176–178CrossRefPubMed Hibbert EJ, Fulcher GR, Coyle L, Gates F, Clifton-Bligh P, Stiel D (1999) Effect of venesection on bone mineral density in an eugonadal woman with haemochromatosis. J Gastroenterol Hepatol 14:176–178CrossRefPubMed
Metadata
Title
Endocrine dysfunction in hereditary hemochromatosis
Authors
C. Pelusi
D. I. Gasparini
N. Bianchi
R. Pasquali
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 8/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0451-7

Other articles of this Issue 8/2016

Journal of Endocrinological Investigation 8/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine